Ocular hypertension or Open angle Glaucoma with no previous treatment.
Conditions
Interventions
33 Patients will be allocated in 3 groups includind 11 patients in each, following permuted- block randomization method (Block size=3
allocation rate 1:1:1). These patients will be treated with fixed combination of prostaglandin/timolol maleate monotherapy ( one daily drop) for 3 months, distributed as follows:Group 1- Latanoprost +
Group 2- Bimatoprost + Timolol (BT) and Group 3-Travoprost + Timolol (TT), independently of age, sex or residence.
Clinical data collected will include patients’ demographic data (age and sex). All pa
drug
Q45.060
D02.033.100.624.915
D10.251.355.255.550.700
Sponsors
Universidade Federal de São Paulo
Universidade Federal de São Paulo
Eligibility
Inclusion criteria
Inclusion criteria: Glaucoma or ocular hypertension patients with no previous topical hypotensive treatment.
Exclusion criteria
Exclusion criteria: Previous ocular surgery, active ocular inflammation or clinically diagnosed dry eye.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Ocular Surface Changes induced by medications used evaluated by break-up time ( TBUT: normal values over 15 seconds), Schirmmer test (normal above 15mm),Green Lissamine vital stainig ( graduated from zero to 9)and changes of score values of OSDI form between inicial and final evaluation. Celular architecture will be evaluated using impression cytology technique and inflammatory parameters will be detected by immunohistochemistry ( HLA-DR and IL-6). | — |
Primary
| Measure | Time frame |
|---|---|
| IOP Reduction evaluated by ocular tonometry with Goldman Tonometry always at same time (8 am), comparing IOP measurements media pre and post-treatment | — |
Countries
Brazil
Contacts
Public ContactHeloisa Giacometti
Federal University of Sao Paulo
Outcome results
None listed